Connor, Clark & Lunn Investment Management (CC&L)’s Assembly Biosciences ASMB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-10,182
| Closed | -$97.3K | – | 1501 |
|
|
2025
Q1 | $97.3K | Sell |
10,182
-631
| -6% | -$6.03K | ﹤0.01% | 1352 |
|
|
2024
Q4 | $171K | Buy |
+10,813
| New | +$171K | ﹤0.01% | 1340 |
|
|
2023
Q1 | – | Sell |
-5,449
| Closed | -$85K | – | 1236 |
|
|
2022
Q4 | $85K | Sell |
5,449
-5,364
| -50% | -$83.7K | ﹤0.01% | 1121 |
|
|
2022
Q3 | $213K | Sell |
10,813
-1,097
| -9% | -$21.6K | ﹤0.01% | 986 |
|
|
2022
Q2 | $300K | Sell |
11,910
-1,836
| -13% | -$46.2K | ﹤0.01% | 864 |
|
|
2022
Q1 | $340K | Sell |
13,746
-439
| -3% | -$10.9K | ﹤0.01% | 848 |
|
|
2021
Q4 | $397K | Buy |
14,185
+1,150
| +9% | +$32.2K | ﹤0.01% | 842 |
|
|
2021
Q3 | $544K | Buy |
13,035
+395
| +3% | +$16.5K | ﹤0.01% | 756 |
|
|
2021
Q2 | $589K | Buy |
12,640
+1,078
| +9% | +$50.2K | ﹤0.01% | 760 |
|
|
2021
Q1 | $638K | Buy |
+11,562
| New | +$638K | ﹤0.01% | 761 |
|
|
2020
Q2 | – | Sell |
-1,333
| Closed | -$237K | – | 1007 |
|
|
2020
Q1 | $237K | Buy |
+1,333
| New | +$237K | ﹤0.01% | 840 |
|